• Professor, McMaster University, Department of Chemistry and Chemical Biology
  • Chief Executive Officer, Centre for Probe Development and Commercialization

John Valliant, Ph.D

Dr. Valliant, a Professor in the Department of Chemistry and Chemical Biology at McMaster University, is internationally recognized for his work in radiopharmaceutical chemistry. His current research focuses on developing new radiolabeling methods and compound discovery strategies to create clinically relevant molecular imaging probes and therapeutic radiopharmaceuticals.

John is also the Chief Executive Officer of the Centre for Probe Development and Commercialization (CPDC), a not-for-profit corporation established in 2008 through funding from the Federal and Provincial governments, industry and academic partners. The CPDC is focused on bridging the gap between academia and industry, by enabling the development and commercialization of promising imaging probes and associated technologies. The Centre employs more than 70 research scientists, production technologists, quality assurance specialists and regulatory affairs experts focused on discovering, developing and distributing the next generation of molecular imaging probes. The CPDC also plays an important role in Ontario’s health care system, manufacturing and delivering a reliable, daily supply of imaging probes to hospitals across the province.

In 2009, John was selected as one of Canada’s Top 40 Under 40, a distinction that recognizes his work at CPDC and McMaster University to advance molecular imaging probe technologies, improve patient care and spur on economic growth through commercialization of Canadian ideas. The award also acknowledges his commitment to education and training at McMaster and within the imaging industry – a dedication to mentorship that has helped position graduates from the Valliant group to take on key leadership roles in both academic and industry settings in Canada and abroad.

John has published more than 100 papers, patents and conference proceedings. He has been invited to speak at scientific conferences and leading research centres the world over, including the plenary lecture at the 2009 Society of Nuclear Medicine meeting. John completed his PhD at McMaster University, and followed with a post-doctoral fellowship under the joint supervision of professors Alun G. Jones (Harvard) and Alan Davison (MIT). Returning to McMaster in 1999 as an assistant professor, he was promoted to full professor in July 2013.